ChromaDex Corp CDXC has announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs).
- ChromaDex's proprietary healthy aging ingredient Niagen will be added to multi-ingredient Designs for Health formulas. Click here to read more on Niagen.
- The Company says that Niagen is the world's first and only FDA-safety reviewed and patented form of nicotinamide riboside.
- The new products will be available exclusively through the Company's extensive HCP network.
- The Niagen inclusive formulas will be available to healthcare practitioners through the Designs for Health customers throughout the U.S., Canada, and Australia.
- In October, ChromaDex announced findings from a clinical study of Niagen ingredient (nicotinamide riboside, NR) in patients with ataxia-telangiectasia (AT).
- AT is a rare, inherited neurodegenerative disorder characterized by premature aging, cerebellar degeneration, immunodeficiency, and cancer predisposition.
- The study found that supplementation with NR improved ataxia scores and increased immunoglobulins, or antibodies, in the immune-compromised patients under 18 years.
- Price Action: CDXC shares are up 9.06% at $3.01 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: Long IdeasNewsPenny StocksHealth CareContractsMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in